The DOI matches its Crossref record; 182 of the 184 references it cites were found in a registry or an index; 29 of the 60 sources its claims cite were checked for support.
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk
Open accessAbstract
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of atherosclerosis and a key target for intervention for the primary and secondary prevention of ASCVD. However, despite substantial reduction in LDL-C, patients continue to have recurrent ASCVD events. Hypertriglyceridemia may be an important contributor of this residual risk. Observational and genetic epidemiological data strongly support a causal role of triglycerides (TGs) and the cholesterol content within triglyceride-rich lipoproteins (TGRLs) and/or remnant cholesterol (RC) in the development of ASCVD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
29 of 60 cited sources checked · 14 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the association was attenuated after adjustment for HDL-C”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Epidemiologic Studies of TGs and Risk of CVD
What the sources say
- Partly supportedcites [72] Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA sourceExperimental — accuracy not yet measured
The Results (Triglyceride; page not provided) report that the triglyceride–CHD association weakened after adjustment for both HDL-C and non-HDL-C. The passage does not establish that adjustment for HDL-C alone produced the attenuation described in the claim. (LLM, conf=0.86)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“They found that the strength of an SNP's effect on TG levels correlated strongly with the magnitude of effect on CAD, after adjustment for the SNP's effects on LDL-C and HDL-C”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Genetic Studies of TGs and CVD
What the sources say
- Supportedcites [116] Do, 2013, Common variants associated with plasma triglycerides and risk for coronary artery disease, Nat Genet source
The Abstract states that the strength of a SNP’s effect on triglycerides correlates with its effect on CAD risk even after accounting for its effects on LDL-C and/or HDL-C. It also reports a strong association across 185 SNPs after adjustment for both LDL-C and HDL-C (P = 1×10−9). (LLM, conf=0.95)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a well-known limitation of Mendelian randomization analyses is that they are susceptible to genetic pleiotropy”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Genetic Studies of TGs and CVD
What the sources say
- Supportedcites [110] Musunuru, 2016, Surprises from genetic analyses of lipid risk factors for atherosclerosis, Circ Res source
In “The Mendelian randomization study design,” the paper identifies pleiotropy as a possible shortcoming: a DNA variant may affect disease risk through mechanisms other than the biomarker being tested, undermining the causal inference. This directly supports the cited limitation. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Epidemiologic Studies of TGs and Risk of CVD
What the sources say
- Partly supportedcites [18] Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med sourceExperimental — accuracy not yet measured
The Study Design and Study Population sections describe a randomized, placebo-controlled trial of 3,414 patients, and the Discussion reports no significant reduction in cardiovascular events with extended-release niacin added to intensive statin therapy. This paper establishes the result for one trial, not two: its Discussion says the other large niacin trial, HPS2-THRIVE, was still in follow-up. (LLM, conf=0.88)
- Could not verifycites [19] Crosby, 2014, Loss-of-function mutations in APOC3, triglycerides, and coronary disease, N Engl J Med sourceExperimental — accuracy not yet measured
The Discovery Cohorts and APOC3 loss-of-function results sections describe genetic associations with coronary heart disease, not niacin treatment trials. Searches for extended-release niacin, placebo, background statin therapy, and vascular events found no passage in our copy addressing the two claimed randomized trials. (LLM, conf=0.78)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Volanesorsen (previously known as ISIS-APOC-III RX ) is a second-generation ASO developed to inhibit apoCIII”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Emerging TG-Lowering Therapies
What the sources say
- Partly supportedcites [170] Gaudet, 2015, Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia, N Engl J Med sourceExperimental — accuracy not yet measured
The RESULTS passage describes ISIS 304801 as a second-generation antisense oligonucleotide designed to reduce APOC3 mRNA, supporting the drug class and intended target. Our copy does not identify ISIS 304801 as volanesorsen or ISIS-APOC-III RX, so it does not establish the name equivalence in the citing sentence. (LLM, conf=0.84)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Mendelian randomization studies of variants associated with TGs are commonly affected by the pleiotropic effects of single-nucleotide polymorphisms (SNPs) on multiple metabolic pathways affecting plasma lipids, including HDL-C and LDL-C”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Genetic Studies of TGs and CVD
What the sources say
- Supportedcites [110] Musunuru, 2016, Surprises from genetic analyses of lipid risk factors for atherosclerosis, Circ Res source
In “Plasma triglyceride-rich lipoproteins as causal,” the paper says Mendelian randomization studies using triglyceride-associated SNPs are difficult to interpret because most such SNPs have pleiotropic relationships with lipids. It specifies that 87 of 94 triglyceride-associated lead SNPs were also associated with LDL-C and/or HDL-C. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [115] Ference, 2018, Causal effect of lipids and lipoproteins on atherosclerosis: lessons from genomic studies, Cardiol Clin source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“was nonsignificant after adjustment for non-HDL-C”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Epidemiologic Studies of TGs and Risk of CVD
What the sources say
- Partly supportedcites [72] Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA sourceExperimental — accuracy not yet measured
The Results > Triglyceride section reports a null association between triglycerides and coronary heart disease after adjustment: HR 0.99 (95% CI, 0.94–1.05). However, that result followed adjustment for both HDL-C and non-HDL-C; the passage does not establish that adjustment for non-HDL-C alone made the association nonsignificant. (LLM, conf=0.86)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“TGs were not associated with stroke after adjustment for lipids”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Epidemiologic Studies of TGs and Risk of CVD
What the sources say
- Supportedcites [72] Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA source
The Methods (Statistical Analyses; page not provided) say hazard ratios were progressively adjusted for lipid measures. The Results (Triglyceride; page not provided) report adjusted triglyceride hazard ratios close to 1 for ischemic, hemorrhagic, and unclassified stroke, with confidence intervals spanning 1. This supports the claim as a finding of no statistically significant association after adjustment. (LLM, conf=0.92)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This finding supported the notion that plasma TG levels are an independent causal risk factor for CAD”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Genetic Studies of TGs and CVD
What the sources say
- Partly supportedcites [116] Do, 2013, Common variants associated with plasma triglycerides and risk for coronary artery disease, Nat Genet sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) reports that genetic effects on triglycerides correlate with CAD risk after accounting for effects on LDL-C and HDL-C, supporting the cited finding. But it concludes that triglyceride-rich lipoproteins may causally influence CAD, not that plasma triglyceride levels themselves are an independent causal risk factor. (LLM, conf=0.86)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, addition of fenofibrate to statin therapy did not result in significant beneficial effects on CVD risk”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TG-Lowering Therapies
What the sources say
- Supportedcites [146] Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med source
The Results > Clinical Outcomes section reports no statistically significant reduction in the primary cardiovascular outcome when fenofibrate was added to simvastatin (hazard ratio 0.92; P = 0.32). No page number is provided in our copy. (LLM, conf=0.94)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
- The quote only partly states this claim. 4
- It may state two separate claims as one. 37
- Probably not a substantial claim. 16
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“fasting and nonfasting TG levels were associated with increased risk of coronary heart disease”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Epidemiologic Studies of TGs and Risk of CVD
What the sources say
- Partly supportedcites [72] Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA sourceExperimental — accuracy not yet measured
The Results > Triglyceride section reports an increased CHD risk with triglycerides after adjustment for nonlipid risk factors (HR 1.37), supporting the overall association. It does not report separate fasting and nonfasting estimates for that adjustment alone; the fasting-status estimates it does report are essentially null after further adjustment for HDL-C and non-HDL-C. (LLM, conf=0.84)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mendelian randomization is essentially an RCT that has been performed by nature, because there is a random allocation of alleles to offspring at the time of conception that is unaffected by reverse causation and independent of environmental and genetic confounders”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Epidemiologic Studies of TGs and Risk of CVD
What the sources say
- Partly supportedcites [110] Musunuru, 2016, Surprises from genetic analyses of lipid risk factors for atherosclerosis, Circ Res sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The TG lowering is linear with a dose-dependent effect such that greater absolute reduction is seen in individuals with higher baseline TG levels”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Omega-3 fatty acids
What the sources say
- Supportedcites [148] Mozaffarian, 2011, Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events, J Am Coll Cardiol source
The Cardiovascular Risk Factors section states that triglyceride lowering is linearly dose-dependent and that absolute reductions are greater at higher baseline levels, while noting variable individual responses. Figure 4 also reports a larger reduction per gram of EPA+DHA in trials with higher starting triglycerides. Page numbers were not supplied in the copy. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This phenomenon occurs when the gene variant under study affects more than one pathway; thus, the observed association between the variant and disease risk may not be due to the biomarker of interest”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Genetic Studies of TGs and CVD
What the sources say
- Supportedcites [110] Musunuru, 2016, Surprises from genetic analyses of lipid risk factors for atherosclerosis, Circ Res source
The section “The Mendelian randomization study design” explicitly defines pleiotropy as a DNA variant affecting multiple mechanisms and says that its association with disease risk may therefore not be due to the biomarker in question. (LLM, conf=0.95)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“LOF mutations in LPL are also associated with increased plasma TG levels and risk of ASCVD”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Genetic Studies of TGs and CVD
What the sources say
- Partly supportedcites [128] Wittrup, 1999, Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis, Circulation sourceExperimental — accuracy not yet measured
The Plasma Triglycerides and Postheparin Plasma Lipoprotein Lipase Activity sections report that three LPL substitutions associated with reduced enzyme activity also increased triglycerides. The Risk of Ischemic Heart Disease and Discussion sections report increased risk for Gly188Glu carriers, but say any increase for Asp9Asn and Asn291Ser carriers was borderline at most. The claim overgeneralizes the cardiovascular-risk association across loss-of-function mutations. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [129] Nordestgaard, 1997, Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease, Circulation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“It inhibits adipose tissue lipolysis, which reduces the flux of FFAs to the liver and, therefore, leads to reduced hepatic VLDL synthesis”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Niacin
What the sources say
- Could not verifycites [167] Qin, 2011, Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen, J Biol Chem sourceExperimental — accuracy not yet measured
The Discussion describes excess fatty acid influx and apoC-III’s role in hepatic VLDL assembly, but does not connect either to niacin or inhibition of adipose-tissue lipolysis. Searches for niacin, nicotinic acid, and adipose lipolysis found no passage addressing the claimed mechanism; page numbers were unavailable in our copy. (LLM, conf=0.73)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Could not verify
None of the sources cited for this claim have been checked yet.
In the paper
“However, despite reductions in LDL-C levels with statins and newer lipid-lowering agents, substantial residual risk persists, with the majority of predicted first and recurrent ASCVD events not being averted”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“TGRL remnants have been linked to impaired coronary vasomotor function, decreased brachial artery flow-mediated dilatation, and increased carotid intima media thickness”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TGRLs and Atherosclerosis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In pregnancy, plasma TG levels can increase two-to fourfold during the third trimester owing to physiologic hormonal changes and are generally not clinically important”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Population Distribution and Causes of Hypertriglyceridemia
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Interestingly, Mendelian randomization suggests a causal association of elevated nonfasting RC with low-grade inflammation and ischemic heart disease (IHD), whereas elevated LDL-C associates with IHD but not inflammation”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TGRL and Inflammation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“These postprandial changes in TGs depend on baseline TG levels, fat load in the meal, and time since the last meal”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Fasting vs nonfasting measurement
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, the TGs are catabolized by macrophages and therefore do not accumulate in atherosclerotic plaque.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Measurement of TGs and RC
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although lifestyle modification remains the cornerstone for management of hypertriglyceridemia, many novel drugs are in development and have shown impressive efficacy in lowering TG levels.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Abstract
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Early epidemiologic studies demonstrated that fasting TG levels independently associated with cardiovascular disease (CVD) and correlated well with nonfasting TG levels”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Fasting vs nonfasting measurement
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Other secondary causes of hypertriglyceridemia include pregnancy, hypothyroidism, chronic kidney disease, poorly controlled diabetes and/or metabolic syndrome, and medications”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Population Distribution and Causes of Hypertriglyceridemia
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These include inhibition of hepatic lipase activity and inhibition of hepatic TGRL remnant clearance”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TG Metabolism
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively, these processes lead to enhanced platelet aggregation and clot formation”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TGRL and Inflammation
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Hypertriglyceridemia is frequently associated with concomitant lipoprotein alterations such as decreased high-density lipoprotein (HDL) cholesterol (HDL-C) levels and elevated levels of non-HDL-C; small, dense and total LDL particles; intermediate-density lipoprotein (IDL); and total apolipoprotein CIII (apoCIII), all of which are associated with increased ASCVD risk”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of atherosclerosis and a key target for intervention for the primary and secondary prevention of ASCVD.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Accordingly, several current recommendations support the use of a random, nonfasting lipid profile in clinical practice for CV risk prediction”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Fasting vs nonfasting measurement
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“At these levels, chylomicrons are usually the main carriers of TG in plasma.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Population Distribution and Causes of Hypertriglyceridemia
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Moderately elevated TG concentrations are commonly due to suboptimal lifestyle habits, including diets enriched in simple carbohydrates and/or saturated fats, excess alcohol consumption, obesity, and sedentary behavior.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Population Distribution and Causes of Hypertriglyceridemia
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thyroid hormone is an important regulator of LPL activity and elevated TG levels in hypothyroidism are due to decreased LPL activity”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Population Distribution and Causes of Hypertriglyceridemia
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Circulating plasma apoB-containing lipoproteins penetrate the endothelial cell lining of the artery wall in susceptible regions and enter the intimal space, where they may be trapped by interaction with subendothelial proteoglycans”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Measurement of TGs and RC
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“TGRLs can readily penetrate the arterial wall and are susceptible to retention by connective tissue matrix through interaction of the positively charged residues (arginine and lysine) on apoB with the negatively charged sulfate groups of subendothelial proteoglycans, similar to LDL.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TGRLs and Atherosclerosis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Endothelial dysfunction often precedes the development of atherosclerosis.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TGRLs and Atherosclerosis
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Incomplete lipidation of apoB by MTP leads to its proteasomal degradation with subsequent decrease in VLDL production.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TG Metabolism
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Hypertriglyceridemia is a well-known cause of acute pancreatitis.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Population Distribution and Causes of Hypertriglyceridemia
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Increase in estrogen levels during the third trimester stimulates hepatic VLDL secretion and reduces the clearance of TGs by lipoprotein lipases (LPLs) in the liver and adipose tissues resulting in elevated TG levels”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Population Distribution and Causes of Hypertriglyceridemia
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Hypertriglyceridemia occurs because of increased TG production, altered processing and catabolism of TGRLs, or reduced clearance.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Population Distribution and Causes of Hypertriglyceridemia
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“It is important to note that although apoCIII is a potent inhibitor of LPL activation, recent studies have shown that it has a pleiotropic role in the regulation of TGRL metabolism independent of LPL pathways.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TG Metabolism
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This suggests that the cholesterol content in TGRLs (e.g., RC), rather than the TGs, may be more important in atherogenesis, because it accumulates in atherosclerotic plaque and is in the causal pathway of atherosclerosis.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Measurement of TGs and RC
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“More commonly, the genetic basis for moderate to severe hypertriglyceridemia is polygenic, which can synergize with environmental factors to profoundly alter TG/VLDL production and clearance”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > ESSENTIAL POINTS
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“This notion is of particular interest because the burgeoning epidemics of obesity, metabolic syndrome, and diabetes are associated with a dramatic increase in the prevalence of hypertriglyceridemia and its potential intersection with ASCVD”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, impairment of endothelium-dependent vasodilation and increased oxidative stress may also play a role in promoting endothelial dysfunction”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TGRLs and Atherosclerosis
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The long-term clinical consequences of hepatic steatosis due to pharmacologic apoB or MTP inhibition in humans remain unclear”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TG Metabolism
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The constitutive production and regulation of hepatic apoB plays a key role in VLDL synthesis and secretion, and safeguards against hepatic steatosis.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TG Metabolism
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, in the insulin-resistant state, increased adipocyte lipolysis results in increased FFA flux to the liver, which also fuels the lipidation of apoB leading to increased VLDL production and de novo hepatic lipogenesis”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > ESSENTIAL POINTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At this time, these direct assays to measure RC have limited clinical applicability because they do not measure all RC in the plasma and are labor intensive and costly.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Measurement of TGs and RC
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Within macrophages, cholesterol cannot be metabolized; thus it accumulates, leading to engorged, dysfunctional foam cells.”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Measurement of TGs and RC
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition, equivocal clinical trial results of TG-lowering therapies have raised the question as to whether TGs represent a surrogate for other causal mechanisms at play for atherosclerotic disease”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“nonfasting calculated RC was associated with a stepwise increase in risk of IHD, MI, and all-cause mortality”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Epidemiologic Studies of TGs and Risk of CVD
What the sources say
- Not checked — no full text of the sourcecites [112] Varbo, 2015, Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population, Clin Chem source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
In the paper
“The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study with fenofibrate did not demonstrate a reduction in the rate of the composite primary outcome (CHD death and nonfatal MI) compared with placebo but was associated with a reduction in total CV events”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > TG-Lowering Therapies
What the sources say
- Not checked — no full text of the sourcecites [137] Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“TG reduction is mediated by multiple mechanisms, including increased FA catabolism by peroxisomal b-oxidation, decreased hepatic lipogenesis, and increased clearance of plasma TGs”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Omega-3 fatty acids
What the sources say
- Not checked — no full text of the sourcecites [149] Jacobson, 2012, Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review, J Clin Lipidol source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“It is important to note that most of these observational epidemiologic studies were done in the prestatin era”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Epidemiologic Studies of TGs and Risk of CVD
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“a pooled analysis of the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) and Treating to New Targets (TNT) trials demonstrated that increased TG levels were associated with higher risk of CVD events in statin-treated patients, although the risk was attenuated after adjustment for HDL-C and apoB-to-apoA-I ratio”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Epidemiologic Studies of TGs and Risk of CVD
What the sources say
- Not checked — no full text of the sourcecites [109] Faergeman, 2009, Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease, Am J Cardiol source
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“#30%”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Emerging TG-Lowering Therapies
What the sources say
- Not checked — no full text of the sourcecites [15] Shapiro, 2016, From lipids to inflammation: new approaches to reducing atherosclerotic risk, Circ Res source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
In the paper
“In clinical trials, intramuscular injection of alipogene tiparvovec was associated with reduction in the incidence of pancreatitis and was well tolerated”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Emerging TG-Lowering Therapies
What the sources say
- Not checked — no full text of the sourcecites [172] Gaudet, 2012, Gene therapy for lipoprotein lipase deficiency, Curr Opin Lipidol source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“#20% reduction in plasma TG levels with moderate to intense aerobic exercise”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Emerging TG-Lowering Therapies
What the sources say
- Not checked — no full text of the sourcecites [38] Watts, 2013, Demystifying the management of hypertriglyceridaemia, Nat Rev Cardiol source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“it is established that LDL is the primary causal factor in the development of atherosclerosis”
§ The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk > Emerging TG-Lowering Therapies
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
The paper relies on this without support.
Plasma triglyceride concentrations serve as a surrogate measure of triglyceride-rich lipoproteins and remnant cholesterol.
“Clinically, plasma TG concentrations serve as a surrogate measure of TGRLs and RC.”
The paper relies on this without support.
Residual confounding can limit the ability to draw causal inference from observational studies linking TGs and remnant cholesterol to ASCVD.
“However, the possibility of residual confounding limits the ability to draw causal inference from these observational studies”
The paper relies on this without support.
Elevated TG levels are closely linked to non-HDL-C with high intercorrelation between the variables.
“elevated TG levels are closely linked to non-HDL-C with high intercorrelation between the variables”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Relatives are described as both wild-type and completely deficient
MinorThe imaging statement calls the relatives wild-type while also saying they had complete ANGPTL3 deficiency. The preceding statement attributes complete deficiency to loss-of-function mutations, so the relatives' genetic status is unclear.
“In three wild-type, first-degree relatives with complete ANGPTL deficiency, CT angiography showed no evidence of coronary atherosclerotic plaque ().”
“LOF mutations leading to complete deficiency of ANGPTL are associated with a familial combined hypolipidemia, characterized by extremely low circulating LDL-C, HDL-C, and TG levels (, ).”
Citations
Cites
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Flagged first, then by citations
2 of the 184 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Chait, 2000, Endotext
Cited by
Sorted by citations
Items 301–400 of 568
Yang, Y., Wang, X., & Yang, W. (2024) · Journal of Dairy Science · doi:10.3168/jds.2024-25585 · Cited by 4
Jiang, J., Chen, M., Li, R., Zhu, J., Qin, F., & Peng, Q. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02416-9 · Cited by 7
Guo, S., Wang, C., Hu, T., Lan, L., Ge, Z., Huang, J., Chen, S., Wu, S., & Xue, H. (2025) · Journal of Clinical Hypertension · doi:10.1111/jch.70084 · Cited by 4
“First, cholesterol could accumulate in intimal foam cells, not TG, which makes the RC become the atherogenic content of TRLs [34].”
Triglycerides and T Cells in Cardiovascular Risk
Reilly, N. A., Mulder, J. W. C. M., Dekkers, K. F., Kuipers, T. B., der Zee, L. C. V. V., Mulder, M. T., van Lennep, J. E. R., Jukema, J. W., & Heijmans, B. T. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101359 · Cited by 5
Liu, L., Aa, G., Liu, H., Sun, P., Liu, Y., Zhang, Z., Chen, X., Yang, Q., & Zhou, X. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042389 · Cited by 5
“3,33,34 Notably, a study derived from the PREDIMED (Prevention With Mediterranean Diet) clinical trial found that among individuals at high cardiovascular risk adhering to a Mediterranean diet, RC was linked to an To ascertain the independent effect of RC on prognostic outcomes beyond LDL-C, we…”
Yang, N., Hu, W., He, J. B., Wu, X., Zou, T., Zheng, J., Zhao, C., & Wang, M. (2023) · Journal of Separation Science · doi:10.1002/jssc.202200844 · Cited by 4
Ardissino, D., Colletti, A., Pellizzato, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087358 · Cited by 4
RetractedYan, M., Wang, Z., An, Y., Li, Z., Li, Y., Zhang, H., Li, C., Wang, L., Chen, L., Gao, C., et al. (2024) · Cell Biology International · doi:10.1002/cbin.12150 · Cited by 4
The effect of ambient temperature on lipid metabolism in children: From a prospective cohort study
Zhang, D., Kou, W., Luo, S., Chen, J., An, X., Fang, S., & Liang, X. (2024) · Environmental Research · doi:10.1016/j.envres.2024.119692 · Cited by 4
Liu, J., Teng, T.-Q., Li, Z., Hu, F.-W., Sha, W., Shen, C., Xia, Y., Zhang, Y., & Li, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1471479 · Cited by 4
Aaseth, J., Retterstøl, K., Rootwelt, H., & Farup, P. G. (2025) · Nutrients · doi:10.3390/nu17010189 · Cited by 4
Genomics of Postprandial Lipidomics in the Genetics of Lipid-Lowering Drugs and Diet Network Study
Irvin, M. R., Montasser, M. E., Kind, T., Fan, S., Barupal, D. K., Patki, A., Tanner, R. M., Armstrong, N. D., Ryan, K. A., Claas, S. A., et al. (2021) · Nutrients · doi:10.3390/nu13114000 · Cited by 4
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Wang, Y., Liu, Y., Yang, R., Li, Z., Su, J., Yang, T., Ma, M., Pan, G., Wang, X., Li, L., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01935-7 · Cited by 4
“RC is calculated directly from lipid parameters and is a key component of atherosclerosis with strong atherogenic effects [13, 14].”
MethodEssential Fatty Acids along the Women’s Life Cycle and Promotion of a Well-balanced Metabolism
Marchiori, G. N., Eynard, A. R., & Soria, E. A. (2023) · Current Women s Health Reviews · doi:10.2174/0115734048247312230929092327 · Cited by 4
Zhang, P., Ma, J., Li, D., Li, Q., Qi, Z., Xu, P., Liu, L., Li, H., & Zhang, A. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0101 · Cited by 4
“14 19 Higher remnant-C levels are present more frequently in populations with obesity, diabetes, and atherogenic dyslipidemia, 20 so it is essential to identify the relationship between remnant-C and arterial stiffness.”
5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge
Moore, B. G., Durigova, A., Lamine, F., Chtioui, H., & Salati, E. (2023) · BMJ Case Reports · doi:10.1136/bcr-2023-254871 · Cited by 4
Cederlöf, E. T., Lager, S., Larsson, A. O., Poromaa, I. S., Lindahl, B., Wikström, A., & Christersson, C. (2024) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14813 · Cited by 3
“26,27 This is in line with the finding of a correlation between fibrinogen and cholesterol and triglycerides in this study.”
ResultHirai, H., Higa, M., Morimoto, T., Sakuma, M., Arasaki, O., Nomiyama, T., Node, K., Ueda, S., & Shimabukuro, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010093 · Cited by 4
“In T2DM, possible candidates for residual risks include sdLDL [12], postprandial hypertriglyceridemia [25], and TG-rich lipoproteins [21,25,26].”
BackgroundWoo, J. S., Hong, S. J., Hoon, D., Kim, K. S., Kim, M. H., Lee, J., Jeong, M. H., Jeong, J., Lee, J.-H., Jeon, D. S., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.001 · Cited by 6
Wu, B., Liang, Z., Qiu, L., Wang, J., Huang, Q., Zhuang, T.-P., Hong, S., & Bai, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1258125 · Cited by 4
Stem‐Cell‐Based Small‐Diameter Blood Vessels with 3D Printing
Wang, Y., Wang, X., Chen, J., Wallace, G. G., & Gu, Q. (2024) · Small Science · doi:10.1002/smsc.202400261 · Cited by 3
Bone turnover: the role of lipoproteins in a population-based study
Winckel, T., Friedrich, N., Zylla, S., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02290-y · Cited by 3
“They transport triglycerides, but also cholesterol, to peripheral tissues such as muscles or adipose tissue, where they are hydrolyzed to release free fatty acids (FFA) for energy production or storage in intracellular lipid droplets [2, 3].”
BackgroundShija, V. M., Chen, H., Huang, J., Masanja, F., Zhong, Y., Li, Y., Amoah, K., Zhimin, J., Ndandala, C. B., & Cai, J. (2024) · Aquaculture · doi:10.1016/j.aquaculture.2024.741727 · Cited by 4
Lai, T., Su, Z., Tian, G., Sun, J., & Hu, K. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02372-x · Cited by 3
Zhou, M., Li, J., Lim, J., Xiao, X., Xia, Y.-M., Wang, Q., & Xu, Z. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s531806 · Cited by 3
Li, X.-X., Zhang, J.-Y., Chen, S.-Y., Wu, X., Ma, C., & Shen, H. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07871-y · Cited by 3
“Beyond its role in cardiovascular disease, RC has emerged as an independent risk factor for diabetes development [14].”
Recent insights into the pathophysiology and implications for surgery in atherosclerosis
Liu, L., Wang, Z., Ma, L., & Wu, S. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03655-9 · Cited by 4
Kamrani, F., Imannezhad, M., Rezaee, A. M., Darroudi, S., Kondori, A. Y., Sadatian, S., Shahri, B., Esmaily, H., Bakavoli, A. H., Ghayour‐Mobarhan, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-27681-8 · Cited by 3
“The underlying mechanisms may involve the propensity of RC, compared to LDL-C, to be more readily taken up by scavenger receptors, thereby facilitating plaque formation in the arteries 32,33 .”
Zheng, H., Chen, G., Huo, Z., Lan, Y., Wang, Y., Fu, P., Wu, W., Zheng, H., Wu, K., Huang, Z., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045376 · Cited by 3
“31,42 It should be emphasized that these clinical implications based on observational studies require validation through prospective randomized controlled trials to clarify the actual clinical benefits of differentiated treat-ment strategies across different populations.”
Lu, F., & Yang, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113190 · Cited by 3
Dan, W., Wang, X., Wu, J., Gu, Y., Liu, S., Zhang, H., Chang, X., Shi, C., Yan, H., Xia, M., et al. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117558 · Cited by 3
Prediction of Cardiovascular Disease Risk in the General Population: A GSA-ELM Approach
Lohbare, S., Alleema, N. N., Praveena, S., et al. (2024) · International Conference on Electronics, Computing, Communication and Control Technology (ICECCC) · doi:10.1109/iceccc61767.2024.10593856 · Cited by 3
“[ 21] The bad cholesterol LDL does go down with max Statins and other lipid-lowering medications have been well-tolerated by a sizable population.”
BackgroundZhang, H., Zheng, X., Yan, Z., Guo, L., Zheng, Y., Zhang, D., & Ma, X. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1439699 · Cited by 3
Mei, X., Wang, Y., Sun, R., Dong, Y., Li, Z., Xu, S., Tang, R., & Liu, H. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.103852 · Cited by 3
Jiang, S., Jin, A., Xing, W., & Jing, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1472871 · Cited by 3
Dai, L., Lyu, L., Zhan, W.-Y., Jiang, S., & Zhou, P. (2025) · World Neurosurgery · doi:10.1016/j.wneu.2024.123649 · Cited by 3
Zhang, S., Du, J., Wang, P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240265i · Cited by 3
Zhang, S., Du, J., Wang, P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240265 · Cited by 3
Kusovschi, J. D., Ivanova, A., Gardner, M. S., McGarrah, R. W., Kraus, W. E., Kuklenyik, Z., Pirkle, J. L., & Barr, J. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097931 · Cited by 4
“Fibrates have been historically co-prescribed with statins, as a method of lowering triglycerides, which also contribute to ASCVD risk [11].”
MethodShui, X., Wen, Z., Dong, R., Chen, Z., Tang, L., Tang, W., Wu, Z., & Chen, L. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01872-6 · Cited by 3
“Previously, LDL-C and VLDL-C were identified as biomarkers for cardiovascular risk and treatment targets, however, recent studies revealed their insufficiency [20, 21].”
BackgroundApplication of the VSP near-infrared fluorescence probe in hyperlipidemia viscosity monitoring
Yang, L., Chen, J., Fang, N., Zhu, H., & Li, Z. (2023) · Materials Today Chemistry · doi:10.1016/j.mtchem.2023.101806 · Cited by 3
Li, X., Hu, J.-G., Liao, Q., Wu, Y., & Huo, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1429993 · Cited by 3
Zhao, N., Liu, D., Song, H., Zhang, X., Yan, C., & Han, Y. (2025) · Scientific Reports · doi:10.1038/s41598-024-83925-z · Cited by 3
Remnant cholesterol and suicide attempts in untreated first-episode major depressive disorder
Xu, P., Fan, C., Yan, M., Liu, J.-J., & Zhang, X.-Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1493509 · Cited by 4
Yu, H., Fan, Y., Wang, J., & Liu, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1539114 · Cited by 3
Exploring high-protein diets in the context of cardiac rehabilitation
Davies, I. G. (2023) · Proceedings of The Nutrition Society · doi:10.1017/s0029665123004779 · Cited by 3
Influence of remnant cholesterol levels on carotid intima thickness in type 2 diabetes patients
Liu, R., Xu, T., Gan, L., Chang, C., Peng, Y., Yao, W., Zhai, A., Fang, M., Shang, X., Chang, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71780-x · Cited by 2
“Given the lack of established thresholds for elevated RC, we followed previous literature by categorizing patients into high RC (> 0.67 mmol/L) and low RC ( 0.67 mmol/L) groups based on the median RC value of 0.67 mmol/L in our T2DM cohort 5 .”
MethodInfluentialDong, X., Chen, K., Li, X., Tang, Y., Zhang, R., & Wang, J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1462142 · Cited by 2
The relationship between remnant cholesterol and low testosterone in adult males
Wang, Z., Shen, L.-W., Wu, M., & Yang, Q. (2024) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdae180 · Cited by 2
The impact of remnant lipids on keloid formation: a causal analysis using mendelian randomization
Zhao, Z., Shen, G., Sun, H., Gong, J., & Hu, B. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-03989-3 · Cited by 3
“…that specific lipid parameters, both conventional (e.g., triglycerides and cholesterol) and remnant lipids that are often forgotten but play a potential role in the development of many diseases [10, 11], contribute to keloid formation by modulating inflammatory responses or fibrob-last activity.”
Gao, Y., Lei, T., Dang, P., & Li, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1512662 · Cited by 2
Getz, M. J., Aronoff, J. E., Jenkins, C. L., Ghafoor, S., Vazquez, J., Appel, N., Gatz, M., Cummings, D. K., Hooper, P. L., Beheim, B., et al. (2025) · Evolution Medicine and Public Health · doi:10.1093/emph/eoaf020 · Cited by 2
“LDL cholesterol, HDL cholesterol, non-HDL cholesterol, total cholesterol, triglycerides, and Apo-B are associated with cardiovascular health [46---49].”
Sheng, J., Shi, S., Ma, X., Zhao, H., Gao, G., & Ji, B. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s523139 · Cited by 3
Luo, C., Du, J., & Zhang, C. (2025) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s566696 · Cited by 2
Inoue, K., Fujie, S. J., Uchida, M., Ito, R., Nakao, K., Kanemoto, M., & Iemitsu, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-39903-8 · Cited by 2
Ren, F.-G., Yang, C., Wang, H., et al. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102804 · Cited by 2
Yu, Y., Jiao, Y., Chang, S., Li, Y. G., Shang, K., Song, G., & Yin, C. (2026) · Journal of Health Population and Nutrition · doi:10.1186/s41043-026-01286-x · Cited by 4
“RC has been shown to impair endothelial function by enhancing inflammatory cytokine release and oxidative stress, and is implicated in promoting a prothrombotic vascular environment [16, 17].”
Inia, J. A., Zhang, L. H., Keijzer, N., Worms, N., van Nieuwkoop, A., Ditmarsch, M., Kleer, M. D., Jukema, J. W., Kastelein, J. J. P., Szarek, M. J., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101028 · Cited by 2
“While currently available therapies aim mostly to decrease plasma LDL-C, remnant cholesterol and tri-glycerides are considered to be equally important residual risk factors for CVD (38, 39), and non-HDL-C and ApoB appear to be superior to LDL-C in CVD risk estimation (40).”
Early-pregnancy remnant cholesterol as a modifiable risk factor for gestational diabetes mellitus
Hu, M.-M., Li, S.-Y., Xiang, L.-L., Zhu, Y., Chen, Y.-T., Liu, Y., Chen, Y., Zeng, Y., & Zhong, T. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.04.012 · Cited by 2
Fernandes, V., Pezzarini, M., Márquez, Y., et al. (2026) · Nutrients · doi:10.3390/nu18101528 · Cited by 2
“Triglycerides are strongly influenced by short-term factors such as recent dietary intake, fasting status, and acute metabolic fluctuations, and therefore often remain normal unless individuals present with metabolic syndrome or uncontrolled diabetes [36].”
Blachman-Braun, R., Talavera, J. O., Pérez‐Rodríguez, M., Roy-García, I. A., Rivas-Ruíz, R., Huitrón-Bravo, G. G., & Salmerón, J. (2023) · Journal of Obesity · doi:10.1155/2023/4991684 · Cited by 2
Epidemiology, Control, and Cardiovascular Outcomes of Dyslipidemia in Diabetes
Fan, W., & Wong, N. D. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_32 · Cited by 2
Pootong, A., Kittiteerasack, P., Pattarapanitchai, P., et al. (2023) · Journal of Associated Medical Sciences · doi:10.12982/jams.2024.018 · Cited by 2
Yoshinaga, M., Yuasa, E., Matsuoka, T., Kihara, S., & Yamamoto, H. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64528 · Cited by 2
Is remnant cholesterol a new therapeutic target for preventing hypertension?
Kunimura, A., & Miura, K. (2024) · Hypertension Research · doi:10.1038/s41440-024-01609-7 · Cited by 3
“Remnant cholesterol (RC), the triglyceride-rich precursors to low-density lipoprotein cholesterol (LDL-C), has been regarded as highly atherogenic [1].”
Immunological Implications in Diabetes: A Review on Various Diseases and Conditions
Upadhyay, S., Mazumder, A., Pentela, B., Bansal, P., Agarwal, N., & Baghel, D. S. (2024) · The Natural Products Journal · doi:10.2174/0122103155298605240303181317 · Cited by 2
Diévart, F., Bruckert, É., Aboyans, V., Bekka, S., Boccara, F., Munoz, B. B. B., Emmerich, J., Farnier, M., Gallo, A., Lemesle, G., et al. (2024) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.02.004 · Cited by 3
Cao, B., Li, K., Ke, J., & Zhao, D. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s461330 · Cited by 2
Time course of remnant cholesterol and the risk of heart failure
Liu, X., Zhang, Y., Tian, X., Xu, Q., Xia, X., Chen, S., Liu, F., Wu, S., & Wang, A. (2024) · Endocrine · doi:10.1007/s12020-024-04028-3 · Cited by 2
“The RC represents the amount of cholesterol in triglyceride-rich lipoproteins, which have a low metabolic rate and are extremely atherogenic [31].”
Park, S. (2024) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2024.30.3.173 · Cited by 2
Jia, H., Zhang, L., Liao, H., Li, Y., Liu, P., Shi, Q., Jiang, B., Zhang, X., Jiang, Y., Nie, Z., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1505234 · Cited by 2
Rehman, R., Riaz, S., Arooj, M., Khan, S., Tariq, U., & Fatima, M. (2024) · Natural Product Communications · doi:10.1177/1934578x241301228 · Cited by 4
“41 In place of statins as the fi rst line of defense against hyperlipidemia, diosgenin has been under research as a potential regulator of lipid metabolism disorders.”
Zheng, Z., Lu, H., Wang, X., Yang, Z., Zhang, Y., Li, K., Shen, C., Yin, Z., Sha, M., Ye, J., et al. (2025) · Genomics · doi:10.1016/j.ygeno.2025.111013 · Cited by 2
APOC3 inhibition: The strongest case yet for triglyceride targeting
Shapiro, M. D., & Slipczuk, L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.09.006 · Cited by 2
Self-citationYu, C., Wang, T., Zhu, L., Zhou, W., Bao, H., & Cheng, X. (2025) · BMC Public Health · doi:10.1186/s12889-025-24635-7 · Cited by 3
Teng, T.-Q., Liu, J., Wang, M., Chen, Y., Xu, J.-C., Dong, Z.-H., Jiao, Q.-Y., Zhang, N., & Yu, H. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02663-x · Cited by 3
“Residual cholesterol (RC), an atherogenic cholesterol fraction that excludes low-density lipoprotein cholesterol, contributes meaningfully to atherosclerotic cardiovascular disease risk [6, 7].”
Yang, H., Sun, C., Li, Y., Zhou, Y., Wang, R., & Li, Y. (2025) · Medicine · doi:10.1097/md.0000000000045395 · Cited by 2
“[40,41] Furthermore, serum HS-CRP levels and IR are positively correlated.”
Advancements in microRNA research in dyslipidemia
Zhao, W., Li, N., & YuanMeng, L. I. (2020) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0125 · Cited by 2
Residual Recurrence Risk of Ischemic Cerebrovascular Events: Elements and Implications
Li, J., Li, Z., Lyu, T., Cheng, S., Pu, Y., & Wang, Y. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00733-5 · Cited by 2
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
Noh, S., Mai, K., Shaver, M., Yong, S., MOSTAGHIMI, M., Oh, G., & Radwan, M. M. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.12.011 · Cited by 3
What is really new in triglyceride guidelines?
Hussain, A., Rifai, M. A., Hermel, M., Slipczuk, L. N., & Virani, S. S. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000802 · Cited by 2
Self-citationHypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor
Khan, T. Z., Schatz, U., Bornstein, S. R., & Barbir, M. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.19 · Cited by 2
Yu, M., Hui, N., Hayat, K., Yang, X., Chu, S., Zhang, D., Wang, J., Chen, X., Ding, J., Chi, Y., et al. (2020) · Preprints.org · doi:10.20944/preprints202012.0052.v1 · Cited by 1
chen, L., zhang, T., Rong, C., xu, Z., tang, X., & Hu, H. (2024) · Research Square · doi:10.21203/rs.3.rs-4237089/v1 · Cited by 2
Shrestha, P., Katta, K., Talsma, D. T., Naggi, A., Hillebrands, J., van de Sluis, B., & van den Born, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.798088 · Cited by 1
Kidney Function and Lipid Levels in Older Adults: The Atherosclerosis Risk in Communities Study
Srivastava, S., Coresh, J., Rebholz, C., Grams, M., Matsushita, K., Martin, S., & Shin, J.-I. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100494 · Cited by 1
“Previous studies have demonstrated that an elevated TG or low HDL-C level is associated with higher risk of cardiovascular events and all-cause mortality.(7,8)”
ResultXi, H., Zhang, B., Sun, T., Zhang, J., & Lv, H. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2403071 · Cited by 1
Zhang, P., Wang, K., Hu, T., Xu, M., You, X., Chen, M., Tang, X. L., Hu, H., Jiang, Y., Zhao, W., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202301564rr · Cited by 1
Luo, B., Huang, X., Peng, Y., Luo, H., Chen, L., & Lin, Y. (2024) · Angiology · doi:10.1177/00033197231225862 · Cited by 1
“7,39 The possible reasons may be attributed to the diverse study population and differing study designs.”
InfluentialTang, J., Tang, T., Yu, Q., Tong, X., Liu, C., Chen, C., Hu, S., Zhang, S., You, Y., Wang, C., et al. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0042 · Cited by 1
“30 However, these methods are expensive and time-consuming.”
An ensemble model for predicting dyslipidemia using 3-years continuous physical examination data
Zhang, N., Guo, X., Yu, X., et al. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1464744 · Cited by 1
“…has become a common disease among patients, posing a significant risk for the development and progression of cardiovascular disease and is one of the most important risk factors for atherosclerotic cardiovascular disease, which accounts for the most deaths worldwide (Sandesara et al., 2019).”
BackgroundAssessment of dyslipidemia management in Turkey using a Delphi panel
Si̇nan, Ü. Y., Yılmaz, M. B., Temizhan, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-82780-2 · Cited by 1
Current Perspectives of Diabetic Dyslipidemia and Treatment Modalities
Akkuş, G. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673336501241001093417 · Cited by 2
Lipid management in patients newly referred to a vascular surgery outpatient clinic
Vergouwen, M., Bayrouti, A., Krzyzaniak, H., & Petrasek, P. F. (2025) · JVS-Vascular Insights · doi:10.1016/j.jvsvi.2025.100231 · Cited by 1
Li, K., Wang, P., Wang, Z., Xu, C., Wang, S., Li, Z., & Wang, P. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04131 · Cited by 1
“This improves understanding of CVD [ 53 , 54 ].”
An, Q., Liu, H., Zhang, F., et al. (2025) · Environmental Technology & Innovation · doi:10.1016/j.eti.2025.104294 · Cited by 1
Hu, X., Ma, G., Wang, X., Lin, J., Wang, T., & Chen, G. (2025) · Food, Nutrition and Health. · doi:10.1007/s44403-025-00024-1 · Cited by 1
“Hyperlipidemia increases the risk of forming foam cells and atherosclerotic plaques, subsequently elevating the risk of cardio-vascular diseases, stroke, and other metabolic problems [8, 9].”
Two Sides of Triglycerides in Atherogenesis: An Essential Contributor
Poznyak, A. V., Kozlov, S. G., Babayeva, G. A., Sukhorukov, V. N., & Orekhov, A. N. (2025) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468241291640 · Cited by 1
“21 During secondary prevention in patients who are already on statin therapy, an increase in cardiovascular risk aligns with heightened TRL levels.”
Quan, K.-J., Huang, Z., Nie, S., & Li, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1643218 · Cited by 3
Metadata
- Authors
- Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D.
- Affiliations
- Emory University (US)
- Michael E. DeBakey VA Medical Center (US)
- Oregon Health & Science University (US)
- Corresponding author
- Shapiro, Michael D
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2018-10-11
- Volume
- 40
- Issue
- 2
- Pages
- 537-557
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC6416708
- OpenAlex
- W2896008418
- Cited by
- 608
- References
- 184
- Citations by year
- 2026: 92 · 2025: 103 · 2024: 122 · 2023: 117 · 2022: 62 · 2021: 61 · 2020: 30 · 2019: 18 · 2018: 2
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eCommons - AKU (Aga Khan University) (submittedVersion)
- Funders
- National Institutes of Health (5R01HL132985)
- U.S. Department of Veterans Affairs (09-028)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD043488)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triglycerides, remnant cholesterol, triglyceride-rich lipoproteins, atherosclerotic cardiovascular disease, hypertriglyceridemia, residual cardiovascular risk, VLDL, chylomicrons, LDL cholesterol
- MeSH terms
- Cholesterol, Humans, Lipoproteins, Triglycerides, Hypertriglyceridemia, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
